Rationale: Previously, we demonstrated that a deoxycorticosterone acetate (DOCA)-salt hypertensive mouse model produces cardiac oxidative stress and diastolic dysfunction with preserved systolic function. Oxidative stress has been shown to increase late inward sodium current (I Na ), reducing the net cytosolic Ca 2؉ efflux.
D iastolic dysfunction is characterized by prolonged relaxation of the myocardium, and, untreated, can lead to the clinical syndrome of heart failure with preserved ejection fraction (HFpEF). HFpEF is an increasingly prevalent health burden accounting for significant morbidity, mortality, and health care expenditures. [1] [2] [3] [4] The underlying mechanisms in diastolic dysfunction are not clearly understood, limiting treatment options. 5 Recent large clinical trials using the standard therapies for systolic heart failure have failed to demonstrate improvement, further emphasizing differences in the underlying pathophysiology of diastolic dysfunction. 6 -8 There are several potential mechanisms for diastolic dysfunction. One is increased diastolic Ca 2ϩ resulting in a slowed ventricular relaxation and diastolic dysfunction. Ca 2ϩ is removed from the cytosol during diastole by the sarcoplasmic reticular Ca 2ϩ -ATPase (SERCA) and the Na ϩ /Ca 2ϩ exchanger (NCX). The NCX couples Ca 2ϩ extrusion to the transmembrane Na ϩ gradient. 9 In the failing heart, a small number of the Na ϩ channels fail to inactivate creating a late Na ϩ current (I Na ). 10 -13 The late I Na increases Na ϩ entry into the cell, reducing Ca 2ϩ extrusion by NCX. 14 Because late I Na is increased with oxidative stress, 15 this represents a possible mechanism underlying diastolic dysfunction. Alternatively, myofilament cross-bridge kinetics and response to Ca 2ϩ are regulated 16 -19 and, if altered, could contribute to diastolic dysfunction.
Previously, we have reported a hypertensive mouse model (deoxycorticosterone acetate [DOCA]-salt) of diastolic dysfunction in which oxidative stress is central to the pathology. 20 Ranolazine, a novel anti-ischemic medication, is used clinically to treat angina without lowering blood pressure or heart rate. 21, 22 ROS-induced increases in cardiomyocyte late I Na have been shown to be attenuated in vitro with ranolazine treatment. 15 Therefore, we tested if, in the DOCA-salt model of isolated diastolic dysfunction, treatment with the late I Na blocker ranolazine would improve cardiac relaxation, negating the deleterious effects of increased cardiac oxidative stress.
Methods
An expanded Methods section is available in the online-only Data Supplement.
Generation of DOCA-Salt Mouse Model
Previously, we have shown that this model leads to mild hypertension, myocardial oxidative stress, and diastolic dysfunction. 20 A gradual and mild elevation in blood pressure was induced by unilateral nephrectomy, subcutaneous implantation of a controlledrelease DOCA pellet (0.7 mg/d; Innovative Research of America, Sarasota, FL) and substituting drinking water with 1.05% saline. Control animals underwent a sham operation, had placebo pellet implantation, and received water without salt.
Invasive hemodynamic studies, noninvasive echocardiography, and myocyte isolation were done on postoperative day 14 -18 for DOCA-salt and control mice. All experiments were approved by the University of Illinois at Chicago Animal Care and Use Committee.
Chronic Administration of Ranolazine
A special diet containing 5 mg ranolazine, 0.3 mg P450 inhibitor, and 0.25 mg red food color was pressed into a 1-g nutritionally complete, grain-based tablet (Harlan, Madison, WI). The control diet contained 0.3 mg P450 inhibitor and 0.25 mg yellow food color pressed into the same type of 1-g tablets. DOCA-salt and sham mice consumed daily Ϸ1 g of the special diet from postoperative day 11-18.
Noninvasive Assessment of Diastolic Dysfunction
Mice were anesthetized, maintained at 37°C, and studied by echocardiography (Vevo 770, VisualSonics Inc, Toronto, Canada). M-mode images in the parasternal long-axis and the left ventricular (LV) short-axis views at the midpapillary level were taken. Measurements were averaged from 3 consecutive beats during expiration. LV inflow velocities (E and A waves) were interrogated by conventional pulsed-wave Doppler from the apical 4-chamber view. The mitral annulus longitudinal velocities (Sm, EЈ, and AЈ) were determined by pulsed-wave tissue Doppler from the apical 4-chamber view. Interpretation was done by a 2 investigators blinded to the treatment groups. First, baseline images were acquired. Subse-quently, to determine the acute effect, the mice were injected with 30 mg/kg ranolazine by intraperitoneal route, followed by a second echocardiogram 30 minutes later.
Invasive Assessment of Diastolic Dysfunction
Mice were anesthetized with 1-1.5% isoflurane and maintained at 37°C. The pressure-volume (PV) catheter was inserted into the right common carotid artery and advanced into the LV. Inferior vena cava occlusion was performed via a diaphragm incision. Volume and parallel conductance calibration were performed as previously described. 20 Baseline hemodynamic measurements were obtained, and, subsequently, to determine the acute effect, the mice received an intravenous injection of ranolazine (5 mg/kg) followed by an infusion at 4.8 mg/kg per hour while additional hemodynamic measurements were recorded. Blood samples were obtained during the last 5 minutes of the procedure to determine the plasma ranolazine concentration.
Cell Shortening and Calcium Transient Measurements
The mechanical properties of the cardiomyocytes were assessed using an IonOptix Myocam System (Ionoptix Inc, Milton, MA). Unloaded cardiomyocytes were placed on a glass slide and allowed to adhere for 10 minutes at 37°C. Cardiomyocytes were then imaged with an inverted microscope and perfused with a Tyrode buffer containing 1.2 mmol/L calcium at room temperature. Cardiomyocytes were paced at 0.5, 1, or 2 Hz for 10-ms duration, and sarcomere shortening and relengthening were assessed using the following indices: peak fractional shortening (FS), time to 90% peak shortening, and , the relaxation time constant (a 0 ϩa 1 e t/ , tϭtime). Cardiomyocytes were treated with 10 mol/L ranolazine for 10 minutes before evaluation. Initial experiments were done at room temperature and subsequent studies at 37°C showed no change in the effects of DOCA-salt or ranolazine. For calcium transient measurements, cardiomyocytes were loaded with 1 mol/L Fura 2-AM for 10 minutes at 37°C, and fluorescence measurements were recorded with a dual-excitation fluorescence photomultiplier system (IonOptix). After loading, the cells were washed and resuspended in normal Tyrode solution. The cardiomyocytes were placed then in the cell chamber, stimulated at 0.5, 1, or 2 Hz for 10-ms duration, and imaged through a Fluor ϫ40 objective lens. Cells were exposed to light emitted by a 75-W Xenon lamp and passed though either a 340-or 380-nm wavelength filter. The emitted fluorescence was detected at 510 nm. To take into account any interference, the background fluorescence for each cardiomyocyte was determined by moving the cardiomyocyte out of the view and recording the fluorescence from the bath solution alone.
Studies With Detergent-Extracted (Skinned) Fiber Bundles
We measured myofilament response to Ca 2ϩ under 2 experimental conditions as described in detail in the online-only Data Supplement. In a first series of experiments, the skinned fiber bundles were mounted in a force measuring apparatus and sarcomere length (SL) was adjusted to 2.2 m, using a laser diffraction pattern, and width and thickness were determined for calculation of cross-sectional area. Force was measured over a range of pCa values. Skinned fiber bundles were treated with 10 mol/L ranolazine for 15 minutes before evaluation. In a second series of experiments under different experimental conditions, we determined steady-state Mg-ATPase activity while simultaneously measuring isometric tension in skinned fiber bundles as a function of pCa. In all experiments, skinned fibers were treated with ranolazine or DMSO vehicle for 15 minutes before beginning either tension or tension/ATPase rate measurements. Tension generated was computed from the force/cross-sectional area and data were analyzed in the GraphPad Prism software and fit with a sigmoidal modified Hill equation to generate tension-pCa curves, Hill coefficients, and pCa 50 (pCa value at half-maximum tension). We also determined cross-bridge kinetics by using a quick release/ restretch protocol. The rate constant for force redevelopment, Ktr, provides a measure of the rate of cross-bridge entry into the force generating state. In all experiments, only fiber bundles retaining more than 80% of their initial maximum tension were included in the 
Results

Ranolazine Attenuated Diastolic Dysfunction In Vivo
As previously described, DOCA-salt mice had evidence of diastolic dysfunction with preserved systolic function by transthoracic echocardiography at postoperative days 14 -18 (Table 1) . 20 Intraperitoneal injection of ranolazine improved diastolic dysfunction without affecting systolic function. DOCA-salt mice had significant reductions in tissue mitral annulus early longitudinal (EЈ) velocities and the ratio of early annulus to late annulus (EЈ/AЈ) velocities, which improved to sham levels with ranolazine treatment (Online Figure I ). The ratio of early diastolic filling velocity to the early diastolic mitral annulus velocity (E/EЈ) has been reported to have the highest correlation with invasive hemody-namic measures of diastolic dysfunction. 20, 23 Hypertensive mice had a higher E/EЈ compared with controls, and ranolazine returned this ratio toward normal in hypertensive mice. The mitral inflow velocities, E and A, were similar among the groups, a pseudonormal pattern, as reported before. 20 The changes in relaxation parameters occurred in the absence of valvular regurgitation, LV wall motion abnormalities, or hypertrophy. Despite a slight reduction in FS (%) when comparing sham with DOCA-saltϩranolazine groups, LVEF (%) and septal annulus systolic velocity (Sm) were statistically indistinguishable among the groups, suggesting the treatments had little effect on systolic function (Table 1) . Invasive hemodynamic evaluation confirmed the echocardiographic findings ( Table 2 ). As expected, systolic blood pressure (SBP), diastolic blood pressure (DBP), and LV end-systolic pressure were mildly elevated in DOCA-salt mice compared with sham and sham-treated mice, although DOCA-salt mice treated with ranolazine did not differ significantly from DOCAsalt mice in any of these parameters. As described before, the best fit for the end-diastolic pressure-volume relation (EDPVR) was by the following linear function: pressure end diastole ϭ EDPVRϫvolume end diastole ϩintercept. 20 Hypertensive DOCAsalt mice had a steeper EDPVR compared with DOCA-salttreated and control groups (PϽ0.005; Figure 1B and 1C). The slopes were 0.23Ϯ0.026, 0.17Ϯ0.01, and 0.16Ϯ0.01 mm Hg/ L; for DOCA-salt, DOCA-saltϩranolazine, and sham, respectively. Additionally, the EDPVR in DOCA-salt mice demonstrated a linear response to serum ranolazine levels (correlation coefficientϭ0.70, PϽ0.05; Figure 1E ).
In an additional set of experiments, we treated DOCA-salt mice with ranolazine for 7 days and measured diastolic function using echocardiography to evaluate the effect of chronic ranolazine therapy on myocardial function (Online Table I 
Ranolazine Improved Relaxation in DOCA-Salt Cardiomyocytes
Silberman et al 20 showed that impaired relaxation of cardiomyocytes was the main contributor to diastolic dysfunction in the DOCA-salt hypertensive model, finding no increase in cardiac fibrosis or inflammation. To confirm that ranolazine was working directly on DOCA-salt cardiomyocytes to improve relaxation, freshly isolated ventricular cardiomyocytes were stimulated at 0.5, 1, and 2 Hz at 37°C and assessed. DOCA-salt cardiomyocytes had preserved contractile function, as previously reported 20 (Figure 2A and 2B) . Additionally, treatment with ranolazine did not affect contraction in sham and DOCAsalt mice. In contrast, relaxation was significantly impaired in DOCA-salt mice and improved to normal levels with ranolazine treatment (DOCA-salt, 0.18Ϯ0.02, DOCA-saltϩranolazine, 0.13Ϯ0.01, sham, 0.11Ϯ0.01, shamϩranolazine 0.09Ϯ0.02 seconds; Pϭ0.0004; Figure 2C ). The baseline sarcomere length of cardiac myocytes was significantly reduced in DOCA-salt mice compared with sham mice ( Figure 2D ). Treatment with ranolazine improved resting sarcomere length in the DOCA-salt mice to levels similar to sham, and ranolazine did not affect sham sarcomere length (DOCA-salt, 1.75Ϯ0.01, DOCA-saltϩranolazine, 1.81Ϯ 0.01, sham, 1.85Ϯ0.02, shamϩranolazine, 1.86Ϯ0.02 m; PϽ 0.0001). In the absence of changes in resting Ca 2ϩ (see below), this indicated that myofilament response to Ca 2ϩ may be altered in diastolic dysfunction. Comparable effects were seen at 1 and 2 Hz stimulation rates and physiological temperature (Online Figure II) . The effect of ranolazine in these experiments was reversible on washout (data not shown).
Diastolic Dysfunction Was Independent of Intracellular Calcium Cycling
To elucidate the mechanism underlying the impaired diastolic function in hypertensive mice, Ca 2ϩ transients were measured in freshly isolated ventricular myocytes. Ca 2ϩ transients did not differ significantly between sham and DOCA-salt mice, and the addition of 10 mol/L ranolazine did not affect either group (Figure 3 ). Baseline intracellular Ca 2ϩ was similar in all groups ( Figure 3A) . Additionally, peak intracellular Ca 2ϩ and the rate of Ca 2ϩ release was similar among all 4 groups ( Figure 3B and  3C) . Surprisingly, there was no difference among the rates of intracellular Ca 2ϩ egress among the 4 groups measured as the time constant ( Figure 3D ). This held true at pacing rates of 1 and 2 Hz as well (Online Figure III) . We cannot rule out regional variations in myocyte properties may obscure changes in Ca 2ϩ 
Late I Na Was Not Elevated in DOCA-Salt Mice
Oxidative stress is known to induce late I Na that can be blocked by the antianginal drug ranolazine, and the DOCA-salt model is associated with increased cardiac oxidative stress. 20, 24 Nevertheless, voltage-clamp studies show no increase in late I Na in DOCA-salt cardiomyocytes compared with sham (sham, 0.105Ϯ0.01, shamϩranolazine, 0.113Ϯ0.004, DOCA-salt, 0.101Ϯ0.008, DOCA-saltϩranolazine, 0.114Ϯ0.013; PϭNS) ( Figure 4A ). Integrated late I Na was measured starting at 5% of peak current and ending 40 ms after depolarization. DOCA-salt myocytes accumulated a similar amount of charge as sham. Extracellular addition of 10 mol/L ranolazine did not Hz at 37°C represented as the peak shortening divided by the baseline sarcomere length (nϭ12, PϭNS). B, Time to 90% peak contraction in isolated cardiomyocytes (nϭ12, PϭNS). C, Isolated cardiomyocytes from DOCA-salt mice have a prolonged relaxation constant () compared with control animals. The addition of ranolazine to isolated DOCA-salt cardiomyocytes normalizes relaxation kinetics (nϭ12, *PϽ0.0001 versus all groups). D, The mean diastolic sarcomere length was significantly shorter in the DOCA-salt cardiomyocytes compared with the sham. The addition of ranolazine to the DOCAsalt cardiomyocytes significantly lengthened resting sarcomeres but had no effect on sham cardiomyocytes (nϭ12, *PϽ0.0001 versus all groups). affect the late accumulated charge in DOCA-salt cardiomyocytes, which was similar to that seen for sham and sham treated myocytes ( Figure 4B ).
Skinned Fibers From DOCA-Salt-Treated Hearts Demonstrated Increased Response to Ca 2؉ and Depressed Cross-Bridge Kinetics
To examine directly myofilament function, the Ca 2ϩ sensitivity of steady-state isometric tension development was measured in a first series of experiments with skinned fiber bundles from sham and DOCA-salt heart preparations. With DOCA-salt treatment, the mean steady-state isometric tension demonstrated an increase in maximum tension and a small but significant leftward shift of the pCa-tension relation ( Figure 5, left panel) . Myofilament Ca 2ϩ sensitivity, indexed by pCa 50 , was significantly (PϽ0.02) greater in DOCA-salt than in sham myofilaments ( Figure 5 ). As indicated in Figure  5 , ranolazine treatment reduced maximum tension and returned the DOCA-salt myofilament sensitivity to levels similar to sham fibers with little effect on fiber bundles from sham hearts. The changes in Ca 2ϩ sensitivity are statistically significant and in a direction that explain the decreased diastolic function. Nevertheless, we cannot completely rule out other possible mechanisms for decreased diastolic relaxation. These results imply that resting tension in Ca 2ϩ -free conditions should be increased, although this was not tested here.
To assess whether the fiber bundles from DOCA-salttreated hearts demonstrated altered cross-bridge kinetics, we measured tension development and simultaneously the rate of ATP hydrolysis (Online Figure IV) . As summarized in Table  3 , there was a significant increase in maximum tension of fiber bundles from DOCA-salt-treated hearts compared with shams. Treatment of the fiber bundles from DOCA-salttreated hearts with ranolazine restored tension to the control levels. Nevertheless, measurement of ATPase rates during the development of steady-state tension showed responses different from the tension measurements. There was no significant difference of maximum ATPase rate between fibers from sham controls compared with fibers from DOCA-salt-treated hearts. Treatment of the fibers from DOCA-salt hearts with ranolazine induced a significant increase in ATPase rate. Online Figure IV shows the ATPase rate plotted as a function of tension. The slope of this relation, which provides a measure of tension cost, was significantly depressed in fibers from DOCAsalt-treated hearts compared with shams, implying a slowing of myofilament exit from the cross-bridge cycle ( Table 3 ). 25 Moreover, although ranolazine had no significant effect on the skinned fibers from shams, treatment of the DOCA-salt fibers with ranolazine significantly increased the maximum ATPase rate over that of the fibers from DOCA-salt-treated hearts. We also determined Ktr, which is a measure of the rate of reentry of cross-bridges into force generating states. No change in Ktr was observed under any of the conditions studied. In a separate set of experiments, we measured myofilament calcium sensitivity of fibers from hearts of DOCA-salt mice and DOCA-salt mice chronically treated with ranolazine and confirmed that ranolazine treatment significantly reduces maximal tension in response to Ca 2ϩ in vivo. Although undetected changes in Na ϩ and Ca 2ϩ currents under stretch cannot be completely eliminated as a cause of diastolic dysfunction, because these experiments were carried out in skinned fibers, our data suggest that a major cause is alterations in the myofilaments that are ameliorated by ranolazine.
Myofilament Protein Phosphorylation and Oxidation Analysis
To understand the mechanism whereby hypertension generated changes in myofilament contractile properties, we performed an analysis of myofilament protein abundance and posttranslational modifications. Representative ProQ and Coomassie gels can be seen in Online Figures V and VII. There were no changes in the abundances of myofilaments or the levels of phosphorylation of major myofilament proteins such as myosin binding protein C, troponin I, and myosin light chain 2 (Online Figure VI) . Similar findings were noted with chronic ranolazine administration.
Additionally, there was an increase in S-glutathionylation of myosin binding protein C in DOCA-salt mice ( Figure 6A and 6B). We determined S-glutathionylation levels in DOCAsalt and sham hearts from mice after or without chronic administration of ranolazine, which confirmed our previous results (Online Figure VIII) . These data indicate that there are DOCA-salt-induced changes in the state of critical myofilament proteins, which may explain the changes in myofilament activity.
Discussion
Based on the idea that cardiac oxidative stress is involved in the pathophysiologies of diastolic dysfunction and the late I Na , 15, 20 we investigated the effects of ranolazine, a late I Na Figure 5 . Myofilament Ca 2؉ responsiveness in skinned fiber bundles isolated from DOCA-salt and sham hearts with and without ranolazine. A through D, The mean steady-state isometric tension of skinned fiber bundles is plotted as a function of pCa. DOCA-salt fibers demonstrate a significant (PϽ0.05) increase in maximum tension (44.51Ϯ0.55 mN/mm 2 ; nϭ6) compared with shams (39.7Ϯ0.79 mN/mm 2 ; nϭ6) and DOCA-salt fibers treated with ranolazine (36.03Ϯ1.50 mN/mm 2 ). DOCA-salt fibers demonstrate a significant (PϽ0.05) increase in mean Ca 2ϩ sensitivity (pCa 50 ϭ6.09Ϯ0.01; nϭ6) compared with shams (pCa 50 ϭ6.02Ϯ0.01; nϭ6). Treatment with ranolazine normalized these changes. E, pCatension relations normalized to maximum tension. DOCA-salt fibers (pCa 50 ϭ6.1Ϯ0.02; Hill nϭ3.42Ϯ 0.30) demonstrate a significant increase in mean Ca 2ϩ sensitivity (nϭ6, *PϽ0.05) as compared with shams without DOCA treatment (pCa 50 ϭ6.0Ϯ0.01; Hill nϭ3.80Ϯ0.61), shams with DOCA treatment (pCa 50 ϭ6.0Ϯ0.01; Hill nϭ3.91Ϯ0.50), and fibers from DOCA mice and treated with ranolazine (pCa 50 ϭ6.0Ϯ0.03; Hill nϭ3.71Ϯ1.0). inhibitor, on the mechanical derangements induced in the DOCA-salt hypertensive model of diastolic dysfunction. 24, 26 Mild hypertension in this model resulted in impaired relaxation that improved acutely after ranolazine treatment. Without changes in heart rate or blood pressure, ranolazine rapidly improved relaxation when measured both noninvasively and invasively. EDPVR, the most widely accepted measurement of relaxation, significantly improved in the DOCA-salt mice confirming our noninvasive echocardiographic results. In our study, the EDPVR relationship but not dP/dt min was different between controls and DOCA-salt mice. This discrepancy has been noted in other studies and, given our results, may imply that actinmyosin cross-bridge cycling affects a latter phase of cardiac diastole. 27, 28 Additionally, ranolazine did not significantly affect hemodynamics in the sham mouse. At the cellular level, isolated DOCA-salt cardiomyocytes demonstrated impaired relaxation that improved with ranolazine. Silberman et al 20 reported the DOCA-salt model of diastolic dysfunction was associated with cardiac oxidative stress and targeting of reactive oxygen species production improved diastolic function. We sought to investigate the downstream mediators of the increased oxidant load to better elucidate the mechanisms regulating diastolic function. Oxidative stress is known to modulate a number of proteins important in cardiac function, including the SR Ca 2ϩ release channel, SR Ca 2ϩ pump, the sarcolemmal L-type Ca 2ϩ channel, the sodiumcalcium exchanger, phospholamban, myofilaments, and the late I Na . 15,29 -33 Largely on the basis of the analogy to systolic dysfunction, we expected to find increased diastolic Ca 2ϩ resulting in slowed myocyte relaxation and diastolic dysfunction, but surprisingly, we found no changes in Ca 2ϩ cycling between DOCA-salt and sham mice. Instead, we noted changes in myofilament activity in the absence of changes in Ca 2ϩ handling. This is consistent with other models of diastolic dysfunction including a model of diabetic cardiomyopathy in which similar changes in sarcomere length were reported with no correlative changes in Ca 2ϩ cycling. 16 -18 Previously, it has been reported that myocyte relaxation can be dissociated from the decline of intracellular Ca 2ϩ , 34 and myofilament Ca 2ϩ sensitivity is a consistent functional abnormality seen in dilated cardiomyopathy. 35 These results suggest that although oxidative stress is associated with both systolic and diastolic dysfunction, mediators of these dysfunctions appear to differ. This may help explain the unimpressive results treating diastolic dysfunction when using drugs proven to be beneficial in systolic heart failure. 6 -8 In vitro studies demonstrating the effectiveness of ranolazine to treat impaired relaxation have used isolated muscle strips, isolated cardiomyocytes, and working heart preparations. 36, 37 Previous studies in both rabbit and rat models have shown that ranolazine attenuates diastolic dysfunction in ischemia/reperfusion. 38, 39 Additionally, in a dog model of chronic heart failure, ranolazine reduces LVEDP. 40 -42 Finally, trials in humans with ischemic heart disease and type 3 long-QT syndrome have supported a role for ranolazine in the treatment of diastolic dysfunction. 43, 44 The mechanism for this effect was thought to be a reduction in late I Na with a subsequent reduction in diastolic Ca 2ϩ . Despite the efficacy of ranolazine in the relief of diastolic dysfunction, no increase in late I Na in the DOCA-salt cardiomyocytes was noted, nor were there changes in calcium cycling to indicate significant alterations in Ca 2ϩ handling in this form of diastolic dysfunction. On the other hand, at rest, the DOCA-salt myocytes had a significant decrease in sarcomere length in the absence of changes in Ca 2ϩ concentration, suggesting increased diastolic tension compared with sham mice. Myofilaments from diastolic dysfunction mice had increased maximum tension and sensitivity to Ca 2ϩ as well as a slowing of cross-bridge exit kinetics compared with sham mice that normalized with ranolazine treatment. Taken together, these results suggest ranolazine improved diastolic function at the cardiomyocyte level through the modulation of myofilament cross-bridge kinetics and sensitivity to Ca 2ϩ . The decrease in sarcomere length in intact cells with no change in passive tension of the muscle strips is consistent with our hypothesis that alterations in cross-bridges are responsible for the changes in diastolic function. This result is consistent with the significance of molecular motors as determinants of relaxation in ejecting hearts. 45 Our investigation of the posttranslational modifications indicated that there was a significant increase in glutathionylation of myosin binding protein C in animals with diastolic dysfunction. Interestingly, accumulating evidence indicates a significant role of myosin binding protein C in control of cross-bridge kinetics. 46 This posttranslational modification supports the hypothesis that hypertension-induced alterations in contractile parameters result from oxidative modification of myosin binding protein C. Inasmuch as acute and direct addition of ranolazine to the skinned fiber bundles enhanced cross-bridge kinetics and the effects of ranolazine were reversible with washout, it seems likely that this agent has direct effects on the myofilaments. Because the effect of ranolazine correlated with myosin binding protein C glutathionylation, the effect of ranolazine was present Figure 6 . A comparison in the posttranslational modifications of the myofilaments from sham and DOCA-salt hearts. A, Western blot analysis demonstrating detection of glutathionylated proteins when comparing myofilament samples from sham and DOCA-salt-treated hearts. The blots were also analyzed for myosin binding protein C, indicating that this protein was the major modification. Note that one pair of comparisons was removed from the gel. B, Quantification of the difference between glutathionylated proteins (GSH) normalized to myosin binding protein C (MyBP-C) in sham and DOCA-salt myofilaments. (*PϽ0.05, nϭ3). only in diastolic dysfunction, and glutathionylation was not altered by ranolazine, oxidative modification of myofilaments may create a binding site for ranolazine to relieve diastolic dysfunction. Future studies will determine the posttranslational modifications, not necessarily limited to phosphorylation and glutathionylation, which may occur to other myofilament proteins, how these modifications influence the modification of other proteins, and what targets are best for therapeutic interventions to obtain a desirable phenotypic response.
Table 3. Effect of Ranolazine on Tension and ATPase Rate of Skinned Fiber Bundles
Measurement of diastolic dysfunction is complicated and controversial. There is no agreement on the best technique. The left ventricular pressure-volume relationship generated during venous occlusion was used in this study because it allows characterization of diastolic function independent of load conditions. Nevertheless, there can be errors in estimating volume because of nonlinearities in the conductancevolume relationship that are more prominent during largevolume deviations. Using only the first 6 pressure-volume loops during venous occlusion resulted in an identical EDPVR, so the likelihood of a sizable error is small. Moreover, in this study, we measured diastolic dysfunction in several different ways and with several different preparations. The effect of ranolazine on diastolic function was seen in vivo by conductance catheter measurements and echocardiography and in vitro using muscle strips and isolated myocytes.
In conclusion, the present study demonstrates that ranolazine treatment improves diastolic function through modulation of myofilament activity. Ranolazine dosing in human studies has shown the therapeutic concentration ranges between 2-6 mol/L. Therefore, we were able to produce an effect on diastolic function in the DOCA-salt mice with roughly the same concentrations used clinically. 26 Our DOCA-salt model is one of the few animal models of diastolic dysfunction in the absence of hypertrophy or changes in ejection fraction, but these results may not be transferable to humans. On the other hand, a human trial suggests that ranolazine may have salutary effects in diastolic dysfunction associated with myocardial injury. 43 
